Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2006, 31(5): 390
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2006 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2006.031.05.997158
Ibutamoren Mesylate
Sorbera, L.A., Bolos, J., Serradell, N.
Growth hormone (GH) is a pleiotropic hormone that is released from the pituitary in a pulsatile manner to promote body growth and fat mobilization and inhibit glucose utilization. The hormone interacts with most tissues of the body and there are therefore numerous pathological endocrine and metabolic conditions that involve or are due to faulty GH secretion. Recombinant GH has been used to treat many of these conditions, but it must be administered by injection and is associated with a number of adverse events. Researchers have speculated that synthetic GH secretagogues (GHSs) may be more effective than recombinant GH in inducing physiological pulsatile GH secretion and have focused on identifying novel GHSs to be used clinically. One promising GHS is the orally active, nonpeptide spironindolinesulfonamide ibutamoren mesilate (MK-0677, L-163194). The agent has exhibited good oral activity and duration of action and was effective clinically for a number of GH-related indications. Ibutamoren is now in phase II development for the treatment of fibromyalgia, Alzheimer's disease and sarcopenia.

Full Text: HTMLPDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences